Search

Your search keyword '"Serrano-Mollar A"' showing total 297 results

Search Constraints

Start Over You searched for: Author "Serrano-Mollar A" Remove constraint Author: "Serrano-Mollar A"
297 results on '"Serrano-Mollar A"'

Search Results

1. Induced pluripotent stem cell-derived lung alveolar epithelial type II cells reduce damage in bleomycin-induced lung fibrosis

2. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells.

3. Differences and Similarities between the Lung Transcriptomic Profiles of COVID-19, COPD, and IPF Patients: A Meta-Analysis Study of Pathophysiological Signaling Pathways

5. Improved Alveolar Dynamics and Structure After Alveolar Epithelial Type II Cell Transplantation in Bleomycin Induced Lung Fibrosis

6. Mechanisms underlying the reversal of fibrotic process following alveolar type II transplantation in bleomycin-induced lung fibrosis animal model

7. Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis

9. Alveolar Type II Cells or Mesenchymal Stem Cells: Comparison of Two Different Cell Therapies for the Treatment of Acute Lung Injury in Rats

12. Profibrotic role of inducible heat shock protein 90α isoform in systemic sclerosis

13. Profibrotic Role of Inducible Heat Shock Protein 90α Isoform in Systemic Sclerosis

17. Alveolar Type II Cells or Mesenchymal Stem Cells: Comparison of Two Different Cell Therapies for the Treatment of Acute Lung Injury in Rats

18. Alveolar Type II Cells or Mesenchymal Stem Cells : Comparison of Two Different Cell Therapies for the Treatment of Acute Lung Injury in Rats

19. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

20. EC50 and CC50 of 39 antiviral drug candidates

21. Gating strategy for the identification of cell subpopulations in the human lung tissue model

22. S4 Fig - Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

23. Antiviral drug candidates for entry inhibition of SARS-CoV-2

24. Gating strategy for the identification of anti-inflammatory effects of selected compounds

25. Optimization of lung tissue enzymatic digestion visualized by t-distributed Stochastic Neighbor Embedding (tSNE), and representative SPC and ACE2 expression

26. Visual summary of the HLT model

27. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

28. Differences and Similarities between the Lung Transcriptomic Profiles of COVID-19, COPD, and IPF Patients: A Meta-Analysis Study of Pathophysiological Signaling Pathways

30. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

31. Cell Therapy in Idiopathic Pulmonary Fibrosis†

32. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

33. Desarrollo de una terapia celular: del laboratorio al hospital

34. Human lung for the study of SARS-CoV-2

37. Improved Alveolar Dynamics and Structure After Alveolar Epithelial Type II Cell Transplantation in Bleomycin Induced Lung Fibrosis

38. Novel Human Lung Tissue Model for the Study of SARS-CoV-2 Entry, Inflammation and New Therapeutics

39. Improved Alveolar Dynamics and Structure After Alveolar Epithelial Type II Cell Transplantation in Bleomycin Induced Lung Fibrosis

40. Evaluation of SARS-CoV-2 Entry, Inflammation and New Therapeutics in Human Lung Tissue Cells

42. Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model.

43. Evaluation of SARS-CoV-2 Entry, Inflammation and New Therapeutics in Human Lung Tissue Cells

44. Poster abstracts

47. Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis

Catalog

Books, media, physical & digital resources